Tumor-associated antigens expressed by allogeneic vaccine cells

Tumor-associated antigens expressed by allogeneic vaccine cells refers to the broad spectrum of immunogenic proteins and glycoproteins presented by whole-cell cancer vaccines derived from non-self (allogeneic) cell lines (Source: PubMed, PMID: 23550143). Unlike single-antigen vaccines, these allogeneic cell-based therapies provide the host immune system with a diverse repertoire of shared antigens common to a specific tumor type, such as MUC1, CEA, or NY-ESO-1 (Source: Journal of Hematology & Oncology, 2013). Upon administration, these irradiated cells are processed by host antigen-presenting cells (APCs), which then cross-present the antigens to T-cells to stimulate a polyclonal anti-tumor immune response (Source: Nature Reviews Cancer, 2004). This approach is designed to address tumor heterogeneity and minimize the risk of immune escape by targeting multiple antigens simultaneously (Source: NIH, NCI Dictionary). Clinical examples of therapies utilizing this target include GVAX and Belagenpumatucel-L, which have been evaluated in various solid malignancies (Source: ClinicalTrials.gov). The use of allogeneic cells allows for a standardized off-the-shelf product that does not require the harvesting of a patient's own tumor tissue. However, the effectiveness of these vaccines often depends on the presence of potent adjuvants or genetic modifications, such as the expression of GM-CSF, to enhance the recruitment and activation of APCs.

Other names

Allogeneic tumor antigensShared tumor-associated antigensWhole-cell vaccine antigensAllogeneic whole-cell vaccine targets

Induction of a polyclonal immune response against multiple tumor-associated antigens through cross-presentation by host dendritic cells.